1-azaspiro[4.4]nonane | 176-03-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 1-azaspiro[4.4]nonane
• CAS: 176-03-4
• 化学式: C₈H₁₅N
• mdl: MFCD14581270
• 分子量: 125.214
• InChiKey: FJGFHPNQSDXCFC-UHFFFAOYSA-N

物化性质

• 沸点：
  182.5±8.0 °C(Predicted)
• 密度：
  0.95±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-azaspiro[4.4]nonane 在 lithium aluminium tetrahydride 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 33.0h， 生成 1-(1-tricyclo[3.3.1.1^3,7]decylmethyl)-1-azaspiro[4.4]nonane
  参考文献：
  名称：

  Synthesis and Antiviral Activity Evaluation of Some New Aminoadamantane Derivatives. 2

  摘要：

  The synthesis of some new aminoadamantane derivatives is described. The new compounds were evaluated against a wide range of viruses [influenza A H1N1, influenza A H2N2, influenza A H3N2, influenza B, parainfluenza 3, herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2), thymidine kinase-deficient (TK-) HSV-1, vaccinia, vesicular stomatitis, polio 1, Coxsackie B4, Sindbis, Semliki forest, Reo 1, varicella-zoster virus (VZV), TK- VZV, human cytomegalo-virus (HCMV),,and human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2)]. Some of them proved markedly active against the influenza A H2N2 (compounds 4a,b, 5a, 6a, and 7a), H3N2 (compounds 5a, 6a, and 7a), and H1N1 (compounds 4b,c and 6d). Since compounds 5a, 6a, and 7a, amantadine, and rimantadine showed the same comparative pattern of potency against influenza strains H2N2, H3N2, and B, it may postulated that they act according to a similar mechanism, with regard to their ''amine'' effect, on the M2 ion channel of influenza A (H1N1, H2N2, or H3N2). In general, no significant activity was noted with any of the new compounds against any of the other viruses tested, making their activity against influenza virus more specific and striking. Borderline activity was noted with some of the compounds (4b,c, 5a-c, and 8a) against HIV-1.

  DOI：

  10.1021/jm950891z
• 作为产物：
  描述：

  1-(2-methoxycarbonylethyl)-1-nitrocyclopentane 在 lithium aluminium tetrahydride 、 palladium 10% on activated carbon 、 氢气 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 61.0h， 生成 1-azaspiro[4.4]nonane
  参考文献：
  名称：

  [EN] SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
  [FR] CARBOXAMIDES N-HÉTÉROCYCLIQUES SUBSTITUÉS, SATURÉS ET INSATURÉS ET COMPOSÉS APPARENTÉS POUR LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES MÉDICAUX

  摘要：

  这项发明提供了替代的、饱和的和不饱和的N-杂环羧酰胺及相关化合物，含有这些化合物的组合物，医疗工具包，以及使用这些化合物和组合物治疗患者的医疗疾病，例如癌症、溶酶体贮积疾病、神经退行性疾病、炎症性疾病等的方法。

  公开号：

  WO2021055630A1

文献信息

• (Indazol-4-YL) Hexahydropyrrolopyrrolones and Methods of Use
  申请人：AbbVie Inc.

  公开号：US20160264582A1

  公开（公告）日：2016-09-15

  Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein G Ar , L 1 , Z 1 and Z 2 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Na v 1.7 and/or Na v 1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

  式（I）的化合物及其药用可接受的盐、酯、酰胺或放射标记形式，其中G、Ar、L1、Z1和Z2如规范中所定义，可用于治疗由电压门控钠通道如Na v 1.7和/或Na v 1.8预防或改善的病症或紊乱。公开了制备这些化合物的方法。还公开了式（I）化合物的药物组合物，以及使用这些化合物和组合物的方法。
• [EN] C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS<br/>[FR] COMPOSÉS DE TÉTRACYCLINE C7-FLUOROSUBSTITUÉE
  申请人：TETRAPHASE PHARMACEUTICALS INC

  公开号：WO2010017470A1

  公开（公告）日：2010-02-11

  The present invention is directed to a compound represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (A) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (A) and its therapeutic use.

  本发明涉及一种由结构式（A）表示的化合物，或其药学上可接受的盐。结构式（A）的变量在此处定义。还描述了包括结构式（A）化合物的药物组合物及其治疗用途。
• [EN] HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROARYLE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE MER
  申请人：DONG A SOCIO HOLDINGS CO LTD

  公开号：WO2018071343A1

  公开（公告）日：2018-04-19

  Compounds of formula (I) [Formula should be inserted here] and a pharmaceutically acceptable salt thereof, wherein A, R1, R2, R3, R4, R5, R6, R7, R24, X, L, n and p are as defined in the specification, are useful for treating or preventing Mer tyrosine kinase receptor modulated disease or conditions. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

  式(I)的化合物及其药学上可接受的盐，其中A、R1、R2、R3、R4、R5、R6、R7、R24、X、L、n和p如规范中定义的那样，可用于治疗或预防Mer酪氨酸激酶受体调节的疾病或症状。还描述了式(I)的化合物的药物组合物，以及使用这些化合物和组合物的方法。
• [EN] PREPARATION OF MIXED AMIDOMAGNESIUM HALIDES<br/>[FR] PRÉPARATION D'HALOGÉNURES MIXTES D'AMIDOMAGNÉSIUM
  申请人：TETRAPHASE PHARMACEUTICALS INC

  公开号：WO2017117189A1

  公开（公告）日：2017-07-06

  A composition, comprising an amidomagnesium chloride represented by the following structural formula R1R2NMgCl, and an amidomagnesium bromide represented by the following structural formula R3R4NMgBr is disclosed. Values and example values of variables R1, R2, R3, and R4 are described herein. The disclosed mixed amidomagnesium halides show an increased solubility, high reactivity and regioselectivity in facilitating the reaction of directed metalation and subsequent functionalization of aryls and heteroaryls.

  披露了一种组合物，包括由以下结构公式表示的酰胺镁氯化物R1R2NMgCl，以及由以下结构公式表示的酰胺镁溴化物R3R4NMgBr。变量R1、R2、R3和R4的值和示例值在本文中进行了描述。所披露的混合酰胺镁卤化物在促进定向金属化反应以及随后芳基和杂芳基的功能化方面显示出增加的溶解度、高反应性和区域选择性。
• SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20180305320A1

  公开（公告）日：2018-10-25

  The present invention relates to compounds according to Formula I: and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.

  本发明涉及式I化合物：以及药用可接受的盐。此类化合物可用于治疗RORgammaT介导的疾病或状况。